Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Wang M (1), Rule S (2), Zinzani PL (3), Goy A (4), Casasnovas O (5), Smith SD (6), Damaj G (7), Doorduijn JK (8), Lamy T (9), Morschhauser F (10), Panizo C (11), Shah B (12), Davies A (13), Eek R (14), Dupuis J (15), Jacobsen E 16, Kater AP (17), Le Gouill S (18), Oberic L (19), Robak T (20), Jain P (21), Frigault MM (22), Izumi R (22), Nguyen D (22), Patel P (22), Yin M (22), Długosz-Danecka M (2)3.
Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1,2,3,4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity . Acalabrutinib was approved in 2017 by the US Food and Drug Administration for the treatment of relapsed/refractory MCL based on clinical data from the open-label, multicenter, phase 2 ACE-LY-004 study of acalabrutinib 100 mg twice daily . Here, we present updated results from the ACE-LY-004 study after a median 26-month follow-up.
CITATION Leukemia. 2019 Sep 26. doi: 10.1038/s41375-019-0575-9.